Takes a 2D ultrasound image and converts it to a 3D image that can be observed by surgeons. GE has a large number of ultrasound machines in the marketplace. Has asked them to adapt VentriPoint's system to their machines. China is also interested in adding their tech to their hospitals.
VentriPoint Diagnostics is a Canadian stock, trading under the symbol VPT-X on the TSX Venture Exchange (VPT-CV). It is usually referred to as TSXV:VPT or VPT-X
In the last year, there was no coverage of VentriPoint Diagnostics published on Stockchase.
VentriPoint Diagnostics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for VentriPoint Diagnostics .
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered VentriPoint Diagnostics In the last year. It is a trending stock that is worth watching.
On 2024-12-12, VentriPoint Diagnostics (VPT-X) stock closed at a price of $0.095.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The company develops and commercializes diagnostic tools to monitor heart disease. Minimal to no revenues so still very speculative. Largely in the development phase. They signed new contracts with GE Healthcare Corp and new patents are being filed. Unlock Premium - Try 5i Free